Stock BMRN BIOMARIN PHARMACEUTICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
82.44 USD -1.62% Intraday chart for BioMarin Pharmaceutical Inc. +1.89% -14.50%
05-03 ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna... Our Logo
04-29 BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioMarin: Q1 Earnings Snapshot
AQ
BioMarin Reports Record Financial Results for the First Quarter 2024
PR
BioMarin Pharmaceutical : IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE - Form 8-K
PU
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
PR
New Data to be presented for BioMarin's VOXZOGO in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
AQ
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
PR
BioMarin Scheduled to Participate in March Investor Conferences
AQ
BioMarin Scheduled to Participate in March Investor Conferences
PR
BioMarin: Q4 Earnings Snapshot
AQ
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
PR
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
PR
BioMarin to Present ROCTAVIAN Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders Congress
AQ
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
PR
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT 1:30 pm ET, in San Francisco, CA
AQ
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
PR
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN for Severe Hemophilia A in Germany
AQ
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
PR
BioMarin Announces Retirement of Jean-Jacques Bienaime, Appoints Alexander Hardy President and Chief Executive Officer
AQ
BioMarin: Q3 Earnings Snapshot
AQ
BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMRN Stock
  4. News BioMarin Pharmaceutical Inc.
  5. Press Releases